High ratio of pCXCR4/CXCR4 tumor infiltrating immune cells in primary high grade ovarian cancer is indicative for response to chemotherapy

• Published in: BMC cancer 2022-04, Vol.22 (1), p.376-376, Article 376
• Main Authors: Walther, Fabio, Berther, Jana Ladina, Lalos, Alexandros, Ramser, Michaela, Eichelberger, Simone, Mechera, Robert, Soysal, Savas, Muenst, Simone, Posabella, Alberto, Güth, Uwe, Stadlmann, Sylvia, Terracciano, Luigi, Droeser, Raoul A, Zeindler, Jasmin, Singer, Gad
• Format: Article
• Language: English
• Subjects: Antibodies; Automation; Biomarkers; Biopsy; Breast cancer; Cancer; Care and treatment; Chemokine receptors; Chemotherapy; CXCL12 protein; CXCR4; CXCR4 protein; Cystadenocarcinoma, Serous - genetics; Cystadenocarcinoma, Serous - pathology; Female; Genetic aspects; Health aspects; Humans; Immune response; Metastasis; Neoplasm Recurrence, Local; Ovarian cancer; Ovarian carcinoma; Ovarian Neoplasms - genetics; Ovarian Neoplasms - pathology; Pathology; Patient outcomes; Patients; PCXCR4; Prognosis; Prognostic significance; Receptors, CXCR4 - genetics; Risk factors; Signal Transduction; Therapeutic targets; Tumor cells; Tumor expression; Tumor infiltrating immune cells; Tumor-infiltrating lymphocytes; Womens health
• ISSN: 1471-2407; 1471-2407
• DOI: 10.1186/s12885-022-09374-x

Ovarian cancer (OC) is the fifth most common malignant female cancer with a high mortality, mainly because of aggressive high-grade serous carcinomas (HGSOC), but also due to absence of specific early symptoms and effective detection strategies. The CXCL12-CXCR4 axis is considered to have a prognostic impact and to serve as potential therapeutic target. Therefore we investigated the role of pCXCR4 and CXCR4 expression of the tumor cells and of tumor infiltrating immune cells (TIC) in high-grade serous OC and their association with the recurrence-free (RFS) and overall survival (OS). A tissue microarray of 47 primary high grade ovarian serous carcinomas and their recurrences was stained with primary antibodies directed against CXCR4 and pCXCR4. Beside the evaluation of the absolute tumor as well as TIC expression in primary and recurrent cancer biopsies the corresponding ratios for pCXCR4 and CXCR4 were generated and analyzed. The clinical endpoints were response to chemotherapy, OS as well as RFS. Patients with a high pCXCR4/CXCR4 TIC ratio in primary cancer biopsies showed a significant longer RFS during the first two years (p = 0.025). However, this effect was lost in the long-term analysis including a follow-up period of 5 years (p = 0.128). Interestingly, the Multivariate Cox regression analysis showed that a high pCXCR4/CXCR4 TIC ratio in primary cancer independently predicts longer RFS (HR 0.33; 95CI 0.13 - 0.81; p = 0.015). Furthermore a high dichotomized distribution of CXCR4 positive tumor expression in recurrent cancer biopsies showed a significantly longer 6-month RFS rate (p = 0.018) in comparison to patients with low CXCR4 positive tumor expression. However, this effect was not independent of known risk factors in a Multivariate Cox regression (HR 0.57; 95CI 0.24 - 1.33; p = 0.193). To the best of our knowledge we show for the first time that a high pCXCR4/CXCR4 TIC ratio in primary HGSOC biopsies is indicative for better RFS and response to chemotherapy. • We observed a significant association between high pCXCR4/CXCR4 TIC ratio and better RFS in primary cancer biopsies, especially during the early postoperative follow-up and independent of known risk factors for recurrence. • High CXCR4 tumor expression in recurrent HGSOC biopsies might be indicative for sensitivity to chemotherapy. We found evidence that at the beginning of the disease (early follow-up) the role of the immune response seems to be the most crucial factor for progression. On